Roche Singapore Technical OperationsRoche Singapore Technical Operations is Roche’s first biologics manufacturing site within Asia region, and the first company in Singapore to produce US FDA licensed bio therapeutics using recombinant DNA technologies.Our Vision and MissionWe will be the most admired biotechnology production operation, respected for our world class innovation, engrained quality inspired people and operational excellence.Quality is every patient’s right and every employee’s responsibility. Quality provides a competitive advantage and is engrained in everything we do, from concept through continuous improvement. Because Roche’s products touch human lives, quality is the true measure of our success.The Business of Improving Human LivesWith over 500 employees, two state-of-the-art facilities, using two different production technology platforms to manufacture bacterial and mammalian cell-based products – all within a 12.6 hectare biomedical space. Here is where we produce the biologic medicines that target a wide spectrum of patients and conditions. Our facilities are designed for multi-product drug substance manufacturing based on CHO and E.Coli platforms. The 26,000 m² CHO facility manufactures Avastin, an anti-angiogenesis therapy for colorectal, lung, kidney, breast and brain cancer patients; and Herceptin, a therapeutic antibody for metastatic breast cancer. The 3,084 m2 E.Coli facility, on the other hand, yields Lucentis, a treatment for patients with wet age-related macular degeneration, a leading cause of blindness in people over 55. The entire operation is supported by external infrastructure which includes a power substation, waste neutralization, industrial gases and water storage.
Roche Singapore Technical OperationsRoche Singapore Technical Operations is Roche’s first biologics manufacturing site within Asia region, and the first company in Singapore to produce US FDA licensed bio therapeutics using recombinant DNA technologies.Our Vision and MissionWe will be the most admired biotechnology production operation, respected for our world class innovation, engrained quality inspired people and operational excellence.Quality is every patient’s right and every employee’s responsibility. Quality provides a competitive advantage and is engrained in everything we do, from concept through continuous improvement. Because Roche’s products touch human lives, quality is the true measure of our success.The Business of Improving Human LivesWith over 500 employees, two state-of-the-art facilities, using two different production technology platforms to manufacture bacterial and mammalian cell-based products – all within a 12.6 hectare biomedical space. Here is where we produce the biologic medicines that target a wide spectrum of patients and conditions. Our facilities are designed for multi-product drug substance manufacturing based on CHO and E.Coli platforms. The 26,000 m² CHO facility manufactures Avastin, an anti-angiogenesis therapy for colorectal, lung, kidney, breast and brain cancer patients; and Herceptin, a therapeutic antibody for metastatic breast cancer. The 3,084 m2 E.Coli facility, on the other hand, yields Lucentis, a treatment for patients with wet age-related macular degeneration, a leading cause of blindness in people over 55. The entire operation is supported by external infrastructure which includes a power substation, waste neutralization, industrial gases and water storage.
Roche Singapore Technical OperationsRoche Singapore Technical Operations is Roche’s first biologics manufacturing site within Asia region, and the first company in Singapore to produce US FDA licensed bio therapeutics using recombinant DNA technologies.Our Vision and MissionWe will be the most admired biotechnology production operation, respected for our world class innovation, engrained quality inspired people and operational excellence.Quality is every patient’s right and every employee’s responsibility. Quality provides a competitive advantage and is engrained in everything we do, from concept through continuous improvement. Because Roche’s products touch human lives, quality is the true measure of our success.The Business of Improving Human LivesWith over 500 employees, two state-of-the-art facilities, using two different production technology platforms to manufacture bacterial and mammalian cell-based products – all within a 12.6 hectare biomedical space. Here is where we produce the biologic medicines that target a wide spectrum of patients and conditions. Our facilities are designed for multi-product drug substance manufacturing based on CHO and E.Coli platforms. The 26,000 m² CHO facility manufactures Avastin, an anti-angiogenesis therapy for colorectal, lung, kidney, breast and brain cancer patients; and Herceptin, a therapeutic antibody for metastatic breast cancer. The 3,084 m2 E.Coli facility, on the other hand, yields Lucentis, a treatment for patients with wet age-related macular degeneration, a leading cause of blindness in people over 55. The entire operation is supported by external infrastructure which includes a power substation, waste neutralization, industrial gases and water storage.